GT Biopharma, Inc.GTBPNASDAQ
Loading
EBITDA Over TimeContracting
Percentile Rank29
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

Percentile
P29
Within normal range
vs 2Y Ago
-5.7x
Contraction
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$-34.32M-160.8%
2024$-13.16M-320.1%
2023$5.98M+128.5%
2022$-20.96M+63.5%
2021$-57.48M-130.2%
2020$-24.97M+31.6%
2019$-36.52M+85.4%
2018$-250.06M-84.5%
2017$-135.57M-1346.4%
2016$-9.37M-